BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 16399589)

  • 1. Using genomics to identify high-risk myeloma after autologous stem cell transplantation.
    Shaughnessy JD; Barlogie B
    Biol Blood Marrow Transplant; 2006 Jan; 12(1 Suppl 1):77-80. PubMed ID: 16399589
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Multiple myeloma--an update on diagnosis and treatment.
    Caers J; Vande broek I; De Raeve H; Michaux L; Trullemans F; Schots R; Van Camp B; Vanderkerken K
    Eur J Haematol; 2008 Nov; 81(5):329-43. PubMed ID: 18637123
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Plasma cell growth fraction using Ki-67 antigen expression identifies a subgroup of multiple myeloma patients displaying short survival within the ISS stage I.
    Gastinne T; Leleu X; Duhamel A; Moreau AS; Franck G; Andrieux J; Lai JL; Coiteux V; Yakoub-Agha I; Bauters F; Harousseau JL; Zandecki M; Facon T;
    Eur J Haematol; 2007 Oct; 79(4):297-304. PubMed ID: 17692103
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Multiple myeloma patients with CKS1B gene amplification have a shorter progression-free survival post-autologous stem cell transplantation.
    Chang H; Qi X; Trieu Y; Xu W; Reader JC; Ning Y; Reece D
    Br J Haematol; 2006 Nov; 135(4):486-91. PubMed ID: 16995883
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combinations of cytogenetics and international scoring system can predict poor prognosis in multiple myeloma after high-dose chemotherapy and autologous stem cell transplantation.
    Inamoto Y; Kurahashi S; Imahashi N; Fukushima N; Adachi T; Kinoshita T; Tsushita K; Miyamura K; Naoe T; Sugiura I
    Am J Hematol; 2009 May; 84(5):283-6. PubMed ID: 19338045
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Predictive factors for survival in myeloma patients who undergo autologous stem cell transplantation: a single-centre experience in 211 patients.
    O'Shea D; Giles C; Terpos E; Perz J; Politou M; Sana V; Naresh K; Lampert I; Samson D; Narat S; Kanfer E; Olavarria E; Apperley JF; Rahemtulla A
    Bone Marrow Transplant; 2006 Apr; 37(8):731-7. PubMed ID: 16501593
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bone marrow plasma cell microaggregates detected by immunohistology predict earlier relapse in patients with minimal disease after high-dose therapy for myeloma.
    Wei A; Westerman D; Feleppa F; Trivett M; Juneja S
    Haematologica; 2005 Aug; 90(8):1147-9. PubMed ID: 16079123
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gene expression profiling defines a high-risk entity of multiple myeloma.
    Zhan FH; Barlogie B; John D S
    Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2007 Apr; 32(2):191-203. PubMed ID: 17478923
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term outcome of myeloablative allogeneic stem cell transplantation for multiple myeloma.
    Kuruvilla J; Shepherd JD; Sutherland HJ; Nevill TJ; Nitta J; Le A; Forrest DL; Hogge DE; Lavoie JC; Nantel SH; Toze CL; Smith CA; Barnett MJ; Song KW
    Biol Blood Marrow Transplant; 2007 Aug; 13(8):925-31. PubMed ID: 17640596
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Deletion of the short arm of chromosome 1 (del 1p) is a strong predictor of poor outcome in myeloma patients undergoing an autotransplant.
    Qazilbash MH; Saliba RM; Ahmed B; Parikh G; Mendoza F; Ashraf N; Hosing C; Flosser T; Weber DM; Wang M; Couriel DR; Popat U; Kebriaei P; Alousi AM; Anderlini P; Naeem RC; Champlin RE; Giralt SA
    Biol Blood Marrow Transplant; 2007 Sep; 13(9):1066-72. PubMed ID: 17697969
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Amplification and overexpression of CKS1B at chromosome band 1q21 is associated with reduced levels of p27Kip1 and an aggressive clinical course in multiple myeloma.
    Shaughnessy J
    Hematology; 2005; 10 Suppl 1():117-26. PubMed ID: 16188652
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Autologous transplantation in elderly patients with multiple myeloma: are we asking the right questions?
    Klepin HD; Hurd DD
    Bone Marrow Transplant; 2006 Nov; 38(9):585-92. PubMed ID: 16953209
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Complete remission status before autologous stem cell transplantation is an important prognostic factor in patients with multiple myeloma undergoing upfront single autologous transplantation.
    Kim JS; Kim K; Cheong JW; Min YH; Suh C; Kim H; Jo DY; Ryoo HM; Yoon SS; Lee JH;
    Biol Blood Marrow Transplant; 2009 Apr; 15(4):463-70. PubMed ID: 19285634
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Post-transplant outcomes of induction therapy for myeloma: thalidomide and dexamethasone versus doxorubicin, vincristine, and dexamethasone prior to high-dose melphalan with autologous stem cell support.
    Vogl DT; Liu SV; Chong EA; Luger SM; Porter DL; Schuster SJ; Tsai DE; Perl A; Loren AW; Goldstein SC; Nasta SD; Andreadis C; Mangan PA; Hummel K; Siegel DL; Glatstein E; Stadtmauer EA
    Am J Hematol; 2007 Dec; 82(12):1071-5. PubMed ID: 17696204
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Insights from the gene expression profiling of multiple myeloma.
    Claudio JO; Masih-Khan E; Stewart AK
    Curr Hematol Rep; 2004 Jan; 3(1):67-73. PubMed ID: 14695854
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic value of chromosome 1q21 gain by fluorescent in situ hybridization and increase CKS1B expression in myeloma.
    Fonseca R; Van Wier SA; Chng WJ; Ketterling R; Lacy MQ; Dispenzieri A; Bergsagel PL; Rajkumar SV; Greipp PR; Litzow MR; Price-Troska T; Henderson KJ; Ahmann GJ; Gertz MA
    Leukemia; 2006 Nov; 20(11):2034-40. PubMed ID: 17024118
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CD221 (IGF-1R) is aberrantly expressed in multiple myeloma, in relation to disease severity.
    Bataille R; Robillard N; Avet-Loiseau H; Harousseau JL; Moreau P
    Haematologica; 2005 May; 90(5):706-7. PubMed ID: 15921396
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Maintenance therapy with thalidomide improves overall survival after autologous hematopoietic progenitor cell transplantation for multiple myeloma.
    Brinker BT; Waller EK; Leong T; Heffner LT; Redei I; Langston AA; Lonial S
    Cancer; 2006 May; 106(10):2171-80. PubMed ID: 16598756
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Higher infused lymphocyte dose predicts higher lymphocyte recovery, which in turn, predicts superior overall survival following autologous hematopoietic stem cell transplantation for multiple myeloma.
    Hiwase DK; Hiwase S; Bailey M; Bollard G; Schwarer AP
    Biol Blood Marrow Transplant; 2008 Jan; 14(1):116-24. PubMed ID: 18158968
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The outcome of autologous stem cell transplantation in patients with plasma cell disorders and dialysis-dependent renal failure.
    Raab MS; Breitkreutz I; Hundemer M; Benner A; Klaus J; Hegenbart U; Moehler T; Ho AD; Zeier M; Goldschmidt H
    Haematologica; 2006 Nov; 91(11):1555-8. PubMed ID: 17082013
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.